|
시장보고서
상품코드
2102089
심장 아밀로이드증 시장 규모, 점유율, 성장 분석 : 진단별, 질환 유형별, 치료법별, 투여 경로별, 최종사용자별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)Cardiac Amyloidosis Market Size, Share, and Growth Analysis, By Diagnosis (Imaging, Biomarker Testing), By Disease Type, By Treatment, By Route of Administration, By End User, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의 심장 아밀로이드증 시장 규모는 2024년에 28억 5,000만 달러로 평가되었으며, 2025년 31억 달러에서 2033년까지 61억 4,000만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 8.9%로 성장할 것으로 전망됩니다.
심장 아밀로이드증 시장은 보험 환급 제도의 영향을 크게 받고 있습니다. 유리한 보험 적용 범위는 환자의 접근성을 향상시키고, 매출 성장을 촉진하기 때문입니다. 다양한 지역에서 예산 제약과의 균형을 맞추면서 치료 선택지를 확대하는 데 초점을 맞춘, 보험 사업자 간의 혁신적인 합의가 이루어지고 있습니다. 이러한 역동적인 상황은 생명공학 기업들이 트랜스사이레틴 생성을 감소시키는 것을 목표로 한 연구로 대표되는, RNA 기반 사일렌서 등 첨단 치료법의 탐구를 촉진하고 있습니다. 그 결과, 확대되는 치료 파이프라인은 기존 약물에 내성이 있는 환자에게 대안을 제공할 뿐만 아니라, 영상 진단 및 바이오마커 서비스에 대한 수요도 자극하고 있습니다. 이러한 추세는 시장 내 성장과 혁신의 지속적인 선순환을 촉진하고 있으며, 심장 아밀로이드증의 관리 및 치료 접근성 측면에서 유망한 미래를 시사하고 있습니다.
세계 심장 아밀로이드증 시장의 성장요인
세계 심장 아밀로이드증 시장은 의료 종사자에 대한 교육 강화와 이 질환과 관련된 증상에 대한 인식을 높이는 광범위한 선별 검사 노력에 의해 크게 견인되고 있습니다. 의료진이 심장 아밀로이드증과 다른 형태의 심근증을 감별하는 전문 지식을 심화함에 따라, 전문 치료 센터로의 의뢰 체계도 더욱 효과적으로 자리 잡고 있습니다. 이러한 인식 제고는 진단 도구 및 치료 솔루션에 대한 수요를 증가시켜, 결과적으로 제약 업계의 투자를 유치하고 시장 성장을 촉진하고 있습니다. 그 결과, 더 많은 환자가 진단과 치료를 받게 되어 지속적인 수익을 창출하는 동시에 혁신적인 치료법에 대한 추가 연구를 촉진하고 있습니다. 또한, 이러한 발전은 임상시험 피험자 모집 과정을 개선하는 협력 네트워크 구축을 촉진하여, 이를 통해 새로운 치료법의 도입을 가속화하고 있습니다.
세계 심장 아밀로이드증 시장의 제약요인
세계 심장 아밀로이드증 치료제 시장은 복잡한 제조 공정과 제한된 시장 경쟁으로 인해 발생하는 신규 치료법의 높은 비용으로 인해 큰 장벽에 직면해 있습니다. 이러한 고가는 보험사에게 과제가 되며, 환자의 본인 부담금 증가로 이어질 가능성이 있습니다. 그 결과, 많은 환자가 치료 시작이 지연되거나 처방받은 치료를 완전히 중단할 우려가 있습니다. 또한, 의료 제도에서는 비용 대비 효과가 중시되는 경우가 많아, 그 결과 보험 적용 약제 목록의 제한이나 사전 승인 요건이 엄격해지면서 적격 환자 중 일부가 필요한 치료를 받지 못하고 있습니다. 이러한 경제적 부담으로 인해 일부 의료진이 최신 치료법의 처방을 주저하게 되어 시장 성장을 더욱 저해하고 있습니다.
세계 심장 아밀로이드증 시장 동향
세계 심장 아밀로이드증 시장은 정밀 진단 기술의 발전에 힘입어 현저한 상승 추세를 보이고 있습니다. 분자 영상 및 바이오마커 프로파일링 분야의 혁신적인 발전으로 다양한 심장 아밀로이드증 아형을 조기에 정확하게 식별할 수 있게 되어, 환자 개개인에 맞춘 치료 전략이 촉진되고 있습니다. 영상 데이터에 인공지능(AI)을 도입함으로써 진단 정확도가 더욱 향상되고, 불확실성이 줄어들며, 적시 개입이 가능해졌습니다. 그 결과, 의료 종사자들은 더욱 견고한 진단 솔루션을 요구하고 있으며, 제조사들은 전략적 제휴에 대한 투자와 규제 당국의 승인 획득에 주력하고 있습니다. 이러한 진화는 환자의 예후를 개선할 뿐만 아니라, 기술 기업들에게 새로운 수익 기회를 창출하고 다양한 의료 현장에서의 시장 침투를 확대하는 결과로 이어지고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 심장 아밀로이드증 시장 규모 : 진단별
세계의 심장 아밀로이드증 시장 규모 : 질환 유형별
세계의 심장 아밀로이드증 시장 규모 : 치료별
세계의 심장 아밀로이드증 시장 규모 : 투여 경로별
세계의 심장 아밀로이드증 시장 규모 : 최종사용자별
세계의 심장 아밀로이드증 시장 규모 : 유통 채널별
세계의 심장 아밀로이드증 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.08.03Global Cardiac Amyloidosis Market size was valued at USD 2.85 Billion in 2024 and is poised to grow from USD 3.1 Billion in 2025 to USD 6.14 Billion by 2033, growing at a CAGR of 8.9% during the forecast period (2026-2033).
The cardiac amyloidosis market is significantly influenced by reimbursement frameworks, as favorable insurance coverage enhances patient access and drives revenue growth. In various regions, innovative agreements among insurance providers have emerged, focusing on balancing budgetary constraints while increasing treatment options. This dynamic landscape propels biotech companies to explore advanced therapies, such as RNA-based silencers, exemplified by studies targeting the reduction of transthyretin production. Consequently, the expanding therapeutic pipeline not only offers alternatives for patients who cannot tolerate existing medications but also stimulates demand for diagnostic imaging and biomarker services. This development fosters a continuous cycle of growth and innovation within the market, signifying a promising future for cardiac amyloidosis management and treatment accessibility.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cardiac Amyloidosis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Cardiac Amyloidosis Market Segments Analysis
Global cardiac amyloidosis market is segmented by diagnosis, disease type, treatment, route of administration, end user, distribution channel and region. Based on diagnosis, the market is segmented into Imaging, Biomarker Testing, Biopsy & Histopathology, Genetic Testing and Others. Based on disease type, the market is segmented into Transthyretin Amyloidosis (ATTR) and Light Chain Amyloidosis (AL). Based on treatment, the market is segmented into Transthyretin Stabilizers, Gene Silencing Therapies, Chemotherapy, Monoclonal Antibodies, Supportive Care and Others. Based on route of administration, the market is segmented into Oral, Intravenous and Subcutaneous. Based on end user, the market is segmented into Hospitals, Specialty Cardiology Clinics, Ambulatory Surgical Centers and Diagnostic Centers. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Cardiac Amyloidosis Market
The global market for cardiac amyloidosis is being significantly driven by enhanced education for healthcare professionals and widespread screening initiatives that improve the recognition of symptoms associated with the condition. As healthcare providers gain expertise in differentiating cardiac amyloidosis from other forms of cardiomyopathy, referral systems to specialized treatment centers are becoming more effective. This increased awareness has amplified the demand for diagnostic tools and therapeutic solutions, which in turn attracts pharmaceutical investment and promotes market growth. As a result, more patients are being diagnosed and managed, generating ongoing revenue and encouraging further research into innovative treatments. Additionally, these advancements facilitate collaborative networks that improve the enrollment process for clinical trials, thereby expediting the introduction of new therapies.
Restraints in the Global Cardiac Amyloidosis Market
The global market for cardiac amyloidosis therapies faces significant obstacles due to the high costs associated with new treatments, which arise from intricate manufacturing processes and limited market competition. These premium prices can create challenges for insurance providers and result in increased out-of-pocket expenses for patients. Consequently, many individuals may experience delays in starting treatment or may even stop their prescribed therapies altogether. Additionally, healthcare systems often focus on cost-effectiveness, leading to restrictive formularies and stringent prior authorization requirements that leave a portion of the eligible patient population without access to needed therapies. This financial strain also dissuades some healthcare professionals from prescribing the latest treatment options, further hindering market growth.
Market Trends of the Global Cardiac Amyloidosis Market
The Global Cardiac Amyloidosis market is experiencing a significant upward trend fueled by advancements in precision diagnostics. Innovative developments in molecular imaging and biomarker profiling are facilitating earlier and more precise identification of various cardiac amyloidosis subtypes, encouraging tailored treatment strategies. The incorporation of artificial intelligence in imaging data further enhances diagnostic accuracy, mitigating uncertainty and fostering timely interventions. Consequently, healthcare providers are increasingly seeking robust diagnostic solutions, spurring manufacturers to invest in strategic collaborations and seek regulatory approvals. This evolution not only leads to improved patient outcomes but also opens new revenue opportunities for technology firms, broadening market penetration across diverse healthcare settings.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Cardiac Amyloidosis Market Size by Diagnosis & CAGR (2026-2033)
- Market Overview
- Imaging
- Biomarker Testing
- Biopsy & Histopathology
- Genetic Testing
- Others
Global Cardiac Amyloidosis Market Size by Disease Type & CAGR (2026-2033)
- Market Overview
- Transthyretin Amyloidosis (ATTR)
- Light Chain Amyloidosis (AL)
Global Cardiac Amyloidosis Market Size by Treatment & CAGR (2026-2033)
- Market Overview
- Transthyretin Stabilizers
- Gene Silencing Therapies
- Chemotherapy
- Monoclonal Antibodies
- Supportive Care
- Others
Global Cardiac Amyloidosis Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Oral
- Intravenous
- Subcutaneous
Global Cardiac Amyloidosis Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Specialty Cardiology Clinics
- Ambulatory Surgical Centers
- Diagnostic Centers
Global Cardiac Amyloidosis Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Cardiac Amyloidosis Market Size & CAGR (2026-2033)
- North America (Diagnosis, Disease Type, Treatment, Route of Administration, End User, Distribution Channel)
- US
- Canada
- Europe (Diagnosis, Disease Type, Treatment, Route of Administration, End User, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Diagnosis, Disease Type, Treatment, Route of Administration, End User, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Diagnosis, Disease Type, Treatment, Route of Administration, End User, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Diagnosis, Disease Type, Treatment, Route of Administration, End User, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Pfizer Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alnylam Pharmaceuticals Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ionnis Pharmaceuticals Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ionis Pharmaceuticals Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BridgeBio Pharma Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eidos Therapeutics Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Intellia Therapeutics Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Prothena Corporation plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alexion Pharmaceuticals Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson Services Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Neurimmune AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AC Immune SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
